Dr. Somer on Treatment Selection Considerations in RCC

Bradley G. Somer, MD
Published: Monday, Jan 07, 2019



Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses treatment selection considerations in renal cell carcinoma (RCC).

In addition to a patient’s risk status, physicians should look at other clinical criteria such as the general health of the patient and their immune factors. The natural biology of the tumor should also be considered, because metastatic sites are important in RCC, says Somer.

For example, a small number of pulmonary metastases with otherwise good risk factors indicates that the patient is angiogenically driven. In that case, surveillance may be sufficient for the patient, adds Somer. However, patients with liver metastases, bone metastases, and brain metastases should receive an aggressive treatment in an attempt to prevent further progression.

Physicians are still searching for biomarkers and other molecular markers that could further direct treatment decisions. PD-L1, although effective in lung and breast cancers, has yet to prove beneficial in RCC, explains Somer.
SELECTED
LANGUAGE


Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses treatment selection considerations in renal cell carcinoma (RCC).

In addition to a patient’s risk status, physicians should look at other clinical criteria such as the general health of the patient and their immune factors. The natural biology of the tumor should also be considered, because metastatic sites are important in RCC, says Somer.

For example, a small number of pulmonary metastases with otherwise good risk factors indicates that the patient is angiogenically driven. In that case, surveillance may be sufficient for the patient, adds Somer. However, patients with liver metastases, bone metastases, and brain metastases should receive an aggressive treatment in an attempt to prevent further progression.

Physicians are still searching for biomarkers and other molecular markers that could further direct treatment decisions. PD-L1, although effective in lung and breast cancers, has yet to prove beneficial in RCC, explains Somer.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x